The purpose of this study is to evaluate the rapid and sustained antidepressant effects of repeat doses of ketamine in the brain. The NIMH is interested in learning how ketamine affects areas of the brain important in regulating mood and if there are unique signatures that could help predict who may respond to the drug. Also, NIMH would like to see if repeated doses of ketamine are safe and effective in treating the symptoms of depression.

This study is enrolling eligible adults, ages 18 to 65, with major depressive disorder. This inpatient study lasts 14-20 weeks and procedures include a medication taper and drug-free period, taking repeated doses of the research drug, taking placebo, multiple brain imaging scans, transcranial magnetic stimulation, and psychological testing. AFTER COMPLETING THE STUDY, PARTICIPANTS CAN RECEIVE SHORT-TERM CARE AT THE NIH WHILE TRANSITIONING BACK TO A PROVIDER.

The study is conducted at the NIH Clinical Center in Bethesda, MD. There is no cost to participate and compensation is provided. This study enrolls eligible participants from across the U.S. Travel arrangements are provided, and costs are covered by NIMH (arrangements vary by distance). After completing the study, participants receive short-term follow-up care at the NIH while transitioning back to a provider.

First steps to participate include calling NIMH, learning study details, asking about your eligibility, and consenting to participate.

To find out if you qualify, email NIMH or call 1-877-646-3644 (1-877-MIND-NIH) [TTY: 1-866-411-1010]. Protocol Number: 17-M-0060. Principal Investigator: Carlos Zarate Jr., M.D.

Scroll to top